Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models charact...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xie, Qian, Bradley, Robert, Kang, Liang, Koeman, Julie, Ascierto, Maria Libera, Worschech, Andrea, De Giorgi, Valeria, Wang, Ena, Kefene, Lisa, Su, Yanli, Essenburg, Curt, Kaufman, Dafna W., DeKoning, Tom, Enter, Mark A., O'Rourke, Timothy J., Marincola, Francesco M., Vande Woude, George F.
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2012
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3258605/
https://ncbi.nlm.nih.gov/pubmed/22203985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1119059109
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares